5,6-diaminouracil hydrochloride | 53608-89-2

• 物质功能分类: 医药中间体 - 杂环化合物 - 嘧啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 5,6-diaminouracil hydrochloride
• CAS: 53608-89-2
• 化学式: C4H7ClN4O2
• 分子量: 178.58
• InChiKey: VHMLWEBEDKTKOQ-UHFFFAOYSA-N

物化性质

• 溶解度：
  DMSO（少许）、水（少许）

计算性质

• 辛醇/水分配系数(LogP)：
  -0.94
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  110
• 氢给体数：
  5
• 氢受体数：
  4

安全信息

• 海关编码：
  2933599090

反应信息

• 作为反应物：
  描述：

  4-甲基苯甲酰甲醛水合物 、 5,6-diaminouracil hydrochloride 以63%的产率得到7-(p-methylphenyl)-2,4(1H,3H)-pteridinedione
  参考文献：
  名称：

  Meester, Johan W. G. De; Plas, Henk C. van der; Middelhoven, Wouter J., Journal of Heterocyclic Chemistry, 1987, vol. 24, p. 441 - 451

  摘要：

  DOI：

文献信息

• Direct Formation of <i>α</i>-Dione blocks from <i>o</i>-Benzoquinone Cycloadditions and their Value in the Synthesis of Fused Quinoxalines, 1,10-Phenanthrolines and Pteridines
  作者：Ronald N. Warrener、Martin R. Johnston、Austin C. Schultz、Mirta Golic、Mark A. Houghton、Maxwell J. Gunter

  DOI：10.1055/s-1998-3135

  日期：1998.6

  o-Benzoquinone reacts with norbornadiene to yield a mixture of exo and endo stereoisomeric bridged α-diones which are condensed with vic-diamines (o-phenylenediamines, 5,6-diamino uracil or 5,6-diaminophenanthroline) to produce the corresponding heterocyclic fused-norbornenes; other rod or angled molrac α-dione blocks and heterocycles derived therefrom are described which open new avenues for macrostructure development via block coupling protocols.

  o-苯醌与诺博尔烯反应，生成外源与内源立体异构的桥连α-二酮混合物，这些α-二酮与维克二胺（邻苯二胺、5,6-二氨基尿嘧啶或5,6-二氨基菲喃啶）缩合，产生相应的具有杂环的融合诺博烯；还描述了其他杆状或角状的莫拉克α-二酮块和由其衍生的杂环，这些新结构为通过块耦合机制开发大分子结构开辟了新途径。
• Synthesis and structure of 6- and 7-(2-arylvinyl)pteridines
  作者：Sayed A. L. Abdel-Hady、Mohamed A. Badawy、Azza M. Kadry、Mosselhi A. N. Mosselhi

  DOI：10.1002/jhet.5570240616

  日期：1987.11

  7-Hydroxy-6-styrylpteridine 9 and 7-(2-arylvinyl)-6-hydroxypteridines 10–12 were synthesized via the condensation of 5,6-diaminouracil 1 with benzylidenepyruvic acids 2–4. The synthesis of the 2-methylthio analogue 15 is also described.

  7-羟基-6-苯乙烯基吡啶9和7-（2-芳基乙烯基）-6-羟基哌啶10-12是通过5,6-二氨基尿嘧啶1与亚苄基丙酮酸2-4的缩合反应合成的。还描述了2-甲硫基类似物15的合成。
• Synthesis and structure of 6- and 7-(acylmethyl)pteridines
  作者：Sayed A. L. Abdel-Hady、Mohamed A. Badawy、Mosselhi A. N. Mosselhi、Yehia A. Ibrahim

  DOI：10.1002/jhet.5570220337

  日期：1985.5

  6-(Acylmethyl)-7-hydroxypteridines 7-14 as well as the isomeric 7-(acylmethyl)-6-hydroxypteridines 15-22 were prepared by condensation of 5,6-diaminouracils 1 and 2 with ethyl aroylpyruvates 3-6 in pyridine and hydrochloric acid, respectively. The structures of the newly synthesized compounds were confirmed by their hydrolysis into the 7-hydroxy-6-methyl-23, 24 and 6-hydroxy-7-methylpteridines 25 and

  通过将5，6-二氨基尿嘧啶1和2与芳酰基丙酮酸乙酯3-6在吡啶中缩合制备6-（酰基甲基）-7-羟基吡啶7-14以及异构体7-（酰基甲基）-6-羟基吡啶15-22。和盐酸。新合成的化合物的结构通过它们的水解确认到7-羟基-6-甲基- 23，24和6-羟基-7- methylpteridines 25和26。还描述了2-（甲硫基）衍生物28的合成。
• Adenosine receptor antagonists and methods of making and using the same
  申请人：Biogen, Inc.

  公开号：US20030225038A1

  公开（公告）日：2003-12-04

  The invention is based on the discovery that compounds of Formula I are unexpectedly highly potent and selective inhibitors of the adenosine A 1 receptor. Adenosine A 1 antagonists can be useful in the prevention and/or treatment of numerous diseases, including cardiac and circulatory disorders, degenerative disorders of the central nervous system, respiratory disorders, and many diseases for which diuretic treatment is suitable. In one embodiment, the invention features a compound of formula I: 1

  本发明基于发现，公式I化合物意外地具有高效和选择性的腺苷A1受体抑制剂作用。腺苷A1拮抗剂可用于预防和/或治疗许多疾病，包括心脏和循环系统疾病、中枢神经系统退行性疾病、呼吸系统疾病以及适用于利尿治疗的许多疾病。在一种实施方式中，本发明涉及公式I的化合物：1。
• ADENOSINE RECEPTOR ANTAGONISTS AND METHODS OF MAKING AND USING THE SAME
  申请人：Ensinger L. Carol

  公开号：US20080004293A1

  公开（公告）日：2008-01-03

  The invention is based on the discovery that compounds of Formula I are unexpectedly highly potent and selective inhibitors of the adenosine A 1 receptor. Adenosine A 1 antagonists can be useful in the prevention and/or treatment of numerous diseases, including cardiac and circulatory disorders, degenerative disorders of the central nervous system, respiratory disorders, and many diseases for which diuretic treatment is suitable. In one embodiment, the invention features a compound of formula I:

  本发明基于发现，公式I化合物是意外地高效和选择性地抑制腺苷A1受体的抑制剂。腺苷A1拮抗剂可以在预防和/或治疗许多疾病方面有用，包括心脏和循环系统疾病、中枢神经系统退行性疾病、呼吸系统疾病以及适用于利尿治疗的许多疾病。在一种实施例中，本发明涉及公式I的化合物：